New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 4, 2013
07:36 EDTFOLDAmicus Theraputics announces positive results from Phase 2 Chaperone-ERT study
Amicus Therapeutics announced positive preliminary results from all 4 dose cohorts in a Phase 2 study to evaluate the safety and pharmacokinetic, or PK, effects of the pharmacological chaperone AT2220 co-administered with enzyme replacement therapy, or ERT, for Pompe disease, Myozyme and Lumizyme. Myozyme and Lumizyme are the first and only approved treatments for Pompe disease. Based on the Study 010 results, Amicus expects to initiate a repeat-dose clinical study in Q3.
News For FOLD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 31, 2015
16:23 EDTFOLDOn The Fly: Top stock stories for Monday
Subscribe for More Information
06:30 EDTFOLDAmicus to host conference call
Subscribe for More Information
06:03 EDTFOLDAmicus agrees to acquire Scioderm
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use